|
|
Article: GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round.
- Article from:
- Blood Weekly
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round (see also GlycoMimetics, Inc.).
"We're delighted to add Genzyme Ventures to our top-tier syndicate of returning investors," said Rachel King, CEO of GlycoMimetics. "Genzyme's participation represents a strong vote of confidence in our pipeline of novel ...
Related newspaper, magazine, and journal articles:
|
|
Article: GlycoMimetics Secures NIH Grant to Study Drug Candidate in ...
Wireless News;
August 20, 2009 ;
525 words
...Wireless News 08-20-2009 GlycoMimetics Secures NIH Grant to Study Drug Candidate in Diabetes Type: News GlycoMimetics, Inc., a clinical-stage biotechnology ... complications of diabetes, and we believe GlycoMimetics' family of small molecule therapeutics ...
|
|